The company delivered a 180 basis point EBITDA margin expansion in FY2025 and achieved its medium-term free cash flow conversion target a year ahead of schedule. Known for its strategic focus on innovation and sustainability, Clariant creates advanced emulsifiers for personal care, catalysts for petrochemical processes, and additives for oil recovery.
Cyborg Score Rationale
Margin expansion and strong cash flow conversion demonstrate operational improvement, but cautious 2026 outlook and macro headwinds including tariff impacts suggest challenges ahead. Strong balance sheet with declining leverage provides financial stability.
Top Insights
FY2025 delivered 180 basis point EBITDA margin expansion with flat sales, indicating strong operational leverage
Net debt declined to CHF 1,413M with leverage improved to 2.03x EBITDA from 2.25x year-prior
April 2024 acquisition of Lucas Meyer Cosmetics from IFF for $810M strengthens Care Chemicals portfolio
Macro headwinds and tariff impacts present challenging 2026 demand environment
Named Competitors
Specialty Catalysts — Petrochemical and refining catalysts
Care Chemicals — Personal care and home care ingredients
Coatings & Adhesives — Specialty coating and adhesive solutions
Recent Developments
(Feb 2026) Reported FY2025 results with 180 bps EBITDA margin expansion and achieved medium-term FCF target early
(Nov 2025) Joint venture with Fuhua Group
(Apr 2024) Acquired Lucas Meyer Cosmetics from International Flavors & Fragrances for $810 million
Open the full interactive Clariant AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.